Shares of Tempus AI (TEM), a technology company focused on advancing precision medicine and patient care through AI, surged 5.91% in the pre-market session on Wednesday. This rally came after the company announced the national launch of its FDA-approved next-generation sequencing test, xT CDx, for comprehensive solid tumor profiling.

xT CDx is a 648-gene test that can detect various types of genetic alterations in solid tumors, including single nucleotide variants, multi-nucleotide variants, insertions, deletions, and microsatellite instability status. It leverages a normal-matched approach, which involves parallel DNA sequencing of tumor and normal patient samples, potentially leading to more accurate identification of cancer-driving somatic variants.

The FDA approval and national launch of xT CDx mark a significant milestone for Tempus AI, as it expands the availability of its trusted and comprehensive genomic profiling solution for cancer patients across the United States. With its extensive gene panel and companion diagnostic claims, xT CDx can provide clinicians with actionable insights to guide targeted therapy selection and improve patient outcomes.